Dymicron
Replace.Restore.Revitalize
Overview
1997
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
High
Balance Sheet
Cash and Cash Equivalents |
$1,202,541 |
Accounts and Notes Receivable |
$40,741 |
Property, Plant and Equipment (PP&E) |
$385,028 |
Total Assets |
$2,488,964 |
Accounts Payable & Accrued Liabilities |
$238,391 |
Long Term Debt |
$45,730,124 |
Total Liabilities |
$68,586,613 |
Total Stockholders' Equity |
$-66,097,649 |
Total Liabilities and Equity |
$2,488,964 |
Statement of Comprehensive Income Information
Total Revenues |
$104,292 |
Costs & Expenses Applicable to Rev |
$49,831 |
Depreciation and Amortization |
$37,236 |
Net Income |
$-4,084,223 |
Earnings Per Share - Basic |
$-0.09 |
Earnings Per Share - Diluted |
$-0.09 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual